Adjuvant Chemo- and Endocrine Therapy Alone or in Combination in Premenopausal Patients (GABG Trial 1)

  • M. Kaufmann
  • W. Jonat
  • U. Abel
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 115)


The natural history of operable breast cancer can be affected by adjuvant treatment (Lippman 1986; Salmon 1987). Adjuvant combination chemotherapy, e.g., cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) results in a significant prolongation of disease-free (DFS) and overall survival (OS) in premenopausal node-positive patients. These data were mainly obtained by overview analyses of randomized trials with treatment groups as compared with no adjuvant therapy (control) after mastectomy.


Breast Cancer Overall Survival Progesterone Receptor Clin Oncol Primary Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anonymous (1987) Adjuvant tamoxifen in early breast cancer. Lancet ii: 191–192Google Scholar
  2. Bonadonna G, Brusamolino E, Valagussa P et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410PubMedCrossRefGoogle Scholar
  3. Bonadonna G, Valagussa P (1985) Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 3: 259–275PubMedGoogle Scholar
  4. Bonadonna G, Valagussa P (1986) Adjuvant chemoendocrine therapy in breast cancer. J Clin Oncol 4: 451–454PubMedGoogle Scholar
  5. Consensus Conference (1985) Adjuvant chemotherapy for breast cancer. JAMA 254: 3461–3463CrossRefGoogle Scholar
  6. EORTC: Breast Cancer Cooperative Group (1973) Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer Clin Oncol 9: 379–381Google Scholar
  7. Fisher B, Redmond C, Brown A et al. (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305: 1–6PubMedCrossRefGoogle Scholar
  8. Fisher B, Redmond C, Brown A et al. (1986) Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4: 459–471PubMedGoogle Scholar
  9. Fisher ER, Sass R, Fisher B et al. (1987) Pathologic findings from the National Surgical Adjuvant Breast Project: Correlations with concordant and discordant estrogen and progesterone receptors. Cancer 59: 1554–1559PubMedCrossRefGoogle Scholar
  10. Gelber RD, Goldhirsch A for the Ludwig Breast Cancer Study Group (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4: 1772–1779PubMedGoogle Scholar
  11. Hubay C, Pearson OH, Marshall US et al. (1980) Antiestrogen, cytotoxic chemotherapy and bacillus Calmette-Guerain vaccination in stage II breast cancer: a preliminary report. Surgery 87: 494–501PubMedGoogle Scholar
  12. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statis Assoc 53: 457–481CrossRefGoogle Scholar
  13. Kaufmann M (1983) Biochemische prognostische Faktoren beim Mamma-Karzinom. In: Kubli F, Nagel GA, Kadach U, Kaufmann M (eds) Neue Wege in der Brustkrebsbehandlung. Zuckschwerdt, Munich, pp 46–61 (Aktuelle onkologie, vol 8 )Google Scholar
  14. Kaufmann M, Jonat W et al. (GABG) (1984) Risk adapted adjuvant chemo-hormonotherapy in operable nodal positive breast cancer. In: Jones SE, Salmon SE (eds) (1984) Adjuvant therapy of cancer, vol 4. Grune and Stratton, New York, pp 369–378Google Scholar
  15. Kaufmann M, Jonat W, Caffier H, Hilfrich J, Melchert F, Mahlke M, Abel U, Maass H, Kubli F for the Gynecological Adjuvant Breast Cancer Group (1985) Adjuvant chemo-hormonotherapy selected by axillary node and hormone receptor status in node-positive breast cancer. Reviews Endocrine-Related Cancer 17: [Suppl] 57–63Google Scholar
  16. Meakin JW (1986) Review of Canadian Trials of adjuvant endocrine therapy for breast cancer. NCI Monogr 1: 111–113PubMedGoogle Scholar
  17. Lippman ME (ed) (1986) NIH Consensus Development Conference on adjuvant chemotherapy and endocrine therapy breast cancer 1985. NCI Monogr 1Google Scholar
  18. Ludwig Breast Cancer Study Group (1984) Randomized trial of chemo-endocrine therapy, endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet i: 1256–1260Google Scholar
  19. Ludwig Breast Cancer Study Group (1985) Chemotherapy with or without oophorectomy high-risk premenopausal patients with operable breast cancer. J Clin Oncol 3: 1059–1067Google Scholar
  20. Nolvadex Adjuvant Trial Organization (NATO) (1985) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years. Lancet i: 836–840Google Scholar
  21. Padmanabhan N, Wang DY, Moore JW, Rubens RD (1987) Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer Clin Oncol 23: 745–748PubMedCrossRefGoogle Scholar
  22. Peto R, Pike MC, Armitage P et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Analysis and examples. Br J Cancer 35: 1–39PubMedCrossRefGoogle Scholar
  23. Rose C, Thorpe S, Anderson KW et al (1985) Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor value. Lancet i: 16–19CrossRefGoogle Scholar
  24. Salmon SE (ed) (1987) Adjuvant therapy of cancer, vol 5. Grune and Stratton, New York Google Scholar
  25. Salmon SE, Jones SE (1979) Studies of the combination of adriamycin and cyclophosphamide (alone or with other agents) for the treatment of breast cancer. Oncology 36: 40–44Google Scholar
  26. Scottish Cancer Trial (1987) Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet ii: 171–175Google Scholar
  27. Wilson RE, Donegan WL, Mettlin C et al. (1984) The 1982 national survey of carcinoma of the breast in the United States. Surg Gynecol Obstet 159: 309–318PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • M. Kaufmann
    • 1
  • W. Jonat
    • 1
  • U. Abel
    • 1
  1. 1.Abteilung für Gynäkologie und GeburtshilfeUniversität HeidelbergHeidelbergGermany

Personalised recommendations